Product Information
GLIMEPIRIDE 4 MG TABLET is a generic product labeled by Legacy Pharmaceutical Packaging, LLC, priced at $0.0507 per EA under NDC 68645057390. Its NADAC has been published 449 times since Feb 28, 2018.
FDA first approved this application on Oct 6, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Glimepiride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
4 mg/1
Manufacturer
Legacy Pharmaceutical Packaging, LLCNDC
68645057390
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GLIMEPIRIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077091FDA Approved
10/6/2005
TE Code
AB
On Market Since
10/6/2005
Pharmacological Classes
Price Statistics
The NADAC for GLIMEPIRIDE 4 MG TABLET has been published 449 times since Feb 28, 2018, and over the history we have for it it has declined 44.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0507 per EA |
|---|---|
| All-time high | $0.0920 (Mar 14, 2018) |
| All-time low | $0.0274 (May 22, 2024) |
| 52-week high | $0.0524 |
| 52-week low | $0.0375 |
| Median price | $0.0496 |
| Average price | $0.0518 |
| Largest weekly change | +73.8% (Jun 19, 2024) |
| Weeks tracked | 449 |
| Tracking since | Feb 28, 2018 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 36% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Legacy Pharmaceutical Packaging, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glimepiride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sulfonylurea class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLIMEPIRIDE 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GLIMEPIRIDE 4 MG TABLET, manufactured by Legacy Pharmaceutical Packaging, LLC, is $0.0507 per EA (NDC 68645057390), effective Sep 30, 2026.
How has the price of GLIMEPIRIDE 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for GLIMEPIRIDE 4 MG TABLET has declined 44.9%. It has been tracked across 449 weekly CMS publications since Feb 28, 2018.
What are the highest and lowest recorded NADAC prices for GLIMEPIRIDE 4 MG TABLET?
Since Feb 28, 2018, the NADAC for GLIMEPIRIDE 4 MG TABLET has ranged from a low of $0.0274 (May 22, 2024) to a high of $0.0920 (Mar 14, 2018), with a median of $0.0496 per EA.
Are there cheaper alternatives to GLIMEPIRIDE 4 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GLIMEPIRIDE 4 MG TABLET, is $0.0323 per EA — about 36% below GLIMEPIRIDE 4 MG TABLET.
Who manufactures GLIMEPIRIDE 4 MG TABLET?
GLIMEPIRIDE 4 MG TABLET (NDC 68645057390) is labeled by Legacy Pharmaceutical Packaging, LLC, and CMS classifies it as a generic product.